2013
DOI: 10.1186/1742-4690-10-52
|View full text |Cite
|
Sign up to set email alerts
|

Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells

Abstract: BackgroundHuman T-cell leukemia virus type-1 (HTLV-1) is the causative retrovirus of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 gene expression is maintained at low levels in vivo by unknown mechanisms. A combination therapy of interferon-α (IFN-α) and zidovudin (AZT) shows therapeutic effects in ATL patients, although its mechanism is also obscure. We previously found that viral gene expression in IL-2-dependent HTLV-1-infected T-cells … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
62
1

Year Published

2013
2013
2024
2024

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 68 publications
(70 citation statements)
references
References 46 publications
3
62
1
Order By: Relevance
“…It might involve an effect both on infected transformed cells that are poorly sensitive to IFN-I but respond to AZT if they have an intact p53 pathway and on noninfected cells present in the microenvironment that should become refractory to infection due to IFN-I (39,56,57). In contrast, IFN-␣ leads only to a minimal decrease in HTLV-1 PVL in HAM/TSP patients (27), suggesting that it cannot allow clearance of HTLV-1-infected cells, but rather, only transiently suppresses viral expression.…”
Section: Discussionmentioning
confidence: 99%
“…It might involve an effect both on infected transformed cells that are poorly sensitive to IFN-I but respond to AZT if they have an intact p53 pathway and on noninfected cells present in the microenvironment that should become refractory to infection due to IFN-I (39,56,57). In contrast, IFN-␣ leads only to a minimal decrease in HTLV-1 PVL in HAM/TSP patients (27), suggesting that it cannot allow clearance of HTLV-1-infected cells, but rather, only transiently suppresses viral expression.…”
Section: Discussionmentioning
confidence: 99%
“…[12][13][14][15][16] These results changed the clinical management of ATL. [16][17][18][19] However, there is yet no direct proof of an antiviral mechanism of action of the drug combination, due to the absence of virological markers that strictly correlate with disease status.…”
Section: Introductionmentioning
confidence: 99%
“…The mechanisms underlying this therapeutic effect remain unclear. In fact, while some groups demonstrated in vitro that the treatment with IFN-␣ decreases HTLV-1 expression, Kannagi's group showed that the level of p19 Gag released in the supernatant is decreased, but not the expression of other viral genes (55). However, the addition of AZT decreases viral transcription and p19 Gag and Tax production, leaving the p53-dependent apoptotic pathways unaffected and restoring the PKR antiviral activity (55).…”
Section: Discussionmentioning
confidence: 99%